- In simple words, what are your doing exactely?
We have developed a process to enrich circulating tumor cells (CTC) from blood (Liquid Biopsy). Primary tumors release at a very early point in time CTCs. Therefore, CTCs are an excellent early indicator for all types of cancer. A huge hurdle in diagnostic is the extreme low concentration of CTCs. In 1ml blood you will find 1 CTC hidden between 50.000.000 white blood cells (after the removal of red blood cells).
- What are your main USPs?
Our technology offers currently the highest enrichment efficiency available on the market: nearly 4log, combined…
…with a target cell recovery rate of >95%.
We have the shortest assay time time compared to our next competitor: 30 min. vs 150 min.
Right from the beginning we are fousing on a fully automated high-throughput approach which matches market needs
- Where do you stand in terms of device development, patents and marketing?
We have a first prototype (pre-production series) up & running which is in daily use by our clinical validation partner Premise Biosystems, Thailand.
Our core technology is protected by a granted patent. Currently we are working on the next patent, following our patent strategy.
Sales & marketing will start in Q4 2018. We have identified our main customers in Europe, the USA and Asia and already warmed up some of them.
- When will you introduce your Cell Enricher Single (CES) and Cell Enricher Multi (CEM)?
The CES first half 2019 and the CEM second half 2019.